{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T11:17:01Z","timestamp":1785237421846,"version":"3.55.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2016,5,17]],"date-time":"2016-05-17T00:00:00Z","timestamp":1463443200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Ratchadapiseksompotch Fund, Faculty of Medicine, Chulalongkorn University","award":["RA 57\/072"],"award-info":[{"award-number":["RA 57\/072"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1007\/s10067-016-3306-x","type":"journal-article","created":{"date-parts":[[2016,5,17]],"date-time":"2016-05-17T11:48:36Z","timestamp":1463485716000},"page":"1673-1681","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Inflammatory cytokine levels, disease activity, and function of patients with rheumatoid arthritis treated with combined conventional disease-modifying antirheumatic drugs or biologics"],"prefix":"10.1007","volume":"35","author":[{"given":"Manathip","family":"Osiri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jongkonnee","family":"Wongpiyabovorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youwanuch","family":"Sattayasomboon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niramol","family":"Thammacharoenrach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,5,17]]},"reference":[{"issue":"Suppl 5","key":"3306_CR1","doi-asserted-by":"crossref","first-page":"v3","DOI":"10.1093\/rheumatology\/kes113","volume":"51","author":"E Choy","year":"2012","unstructured":"Choy E (2012) Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford) 51(Suppl 5):v3\u2013v11","journal-title":"Rheumatology (Oxford)"},{"key":"3306_CR2","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/nri2094","volume":"7","author":"IB McInnes","year":"2007","unstructured":"McInnes IB, Schett G (2007) Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 7:429\u2013442","journal-title":"Nat Rev Immunol"},{"key":"3306_CR3","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1097\/BOR.0000000000000036","volume":"26","author":"AM Gizinski","year":"2014","unstructured":"Gizinski AM, Fox DA (2014) T cell subsets and their role in the pathogenesis of rheumatic disease. Curr Opin Rheumatol 26:204\u2013210","journal-title":"Curr Opin Rheumatol"},{"key":"3306_CR4","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1056\/NEJMra1004965","volume":"365","author":"IB McInnes","year":"2011","unstructured":"McInnes IB, Schett G (2011) The pathogenesis of rheumatoid arthritis. New Engl J Med 365:2205\u20132219","journal-title":"New Engl J Med"},{"key":"3306_CR5","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1093\/rheumatology\/kes304","volume":"52","author":"JL Davignon","year":"2013","unstructured":"Davignon JL, Hayder M, Baron M et al (2013) Targeting monocytes\/macrophages in the treatment of rheumatoid arthritis. Rheumatology (Oxford) 52:590\u2013598","journal-title":"Rheumatology (Oxford)"},{"key":"3306_CR6","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1093\/rheumatology\/ket414","volume":"53","author":"DE Furst","year":"2014","unstructured":"Furst DE, Emery P (2014) Rheumatoid arthritis pathophysiology: update on emerging cytokine and cytokine-associated cell targets. Rheumatology (Oxford) 53:1560\u20131569","journal-title":"Rheumatology (Oxford)"},{"key":"3306_CR7","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/nature12873","volume":"506","author":"Y Okada","year":"2014","unstructured":"Okada Y, Wu D, Trynka G et al (2014) Genetics of rheumatoid arthritis contribute to biology and drug discovery. Nature 506:376\u2013381","journal-title":"Nature"},{"key":"3306_CR8","doi-asserted-by":"crossref","unstructured":"Alunno A, Manetti M, Caterbi S et al. (2015) Altered immunoregulation in rheumatoid arthritis: the role of regulatory T cells and proinflammatory Th17 cells and therapeutic implications. Mediators Inflam 751793","DOI":"10.1155\/2015\/751793"},{"key":"3306_CR9","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1136\/ard.2009.123919","volume":"69","author":"JS Smolen","year":"2010","unstructured":"Smolen JS, Aletaha D, Bijlsma JW et al (2010) Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 69:631\u2013637","journal-title":"Ann Rheum Dis"},{"key":"3306_CR10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","volume":"75","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Breedveld FC, Burmester GR et al (2016) Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis 75:3\u201315","journal-title":"Ann Rheum Dis"},{"key":"3306_CR11","first-page":"1568","volume":"353","author":"T Mottonen","year":"1999","unstructured":"Mottonen T, Hannonen P, Leirisalo-Repo M et al (1999) Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group Lancet 353:1568\u20131573","journal-title":"FIN-RACo trial group. Lancet"},{"key":"3306_CR12","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0140-6736(04)16676-2","volume":"364","author":"C Grigor","year":"2004","unstructured":"Grigor C, Capell H, Stirling A et al (2004) Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 364:263\u2013269","journal-title":"Lancet"},{"key":"3306_CR13","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1002\/art.21405","volume":"52","author":"YP Goekoop-Ruiterman","year":"2005","unstructured":"Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF et al (2005) Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 52:3381\u20133390","journal-title":"Arthritis Rheum"},{"key":"3306_CR14","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1136\/ard.2007.071092","volume":"66","author":"SM Verstappen","year":"2007","unstructured":"Verstappen SM, Jacobs JW, van der Veen MJ et al (2007) Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 66:1443\u20131449","journal-title":"Ann Rheum Dis"},{"key":"3306_CR15","doi-asserted-by":"crossref","first-page":"329","DOI":"10.7326\/0003-4819-156-5-201203060-00004","volume":"156","author":"MF Bakker","year":"2012","unstructured":"Bakker MF, Jacobs JW, Welsing PM et al (2012) Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial. Ann Intern Med 156:329\u2013339","journal-title":"Ann Intern Med"},{"key":"3306_CR16","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1093\/rheumatology\/kes362","volume":"52","author":"S Hirata","year":"2013","unstructured":"Hirata S, Dirven L, Shen Y et al (2013) A multi-biomarker score measures rheumatoid arthritis disease activity in the BeSt study. Rheumatology (Oxford) 52:1202\u20131207","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl 85","key":"3306_CR17","first-page":"S29","volume":"32","author":"OG Segurado","year":"2014","unstructured":"Segurado OG, Sasso EH (2014) Vectra DA for the objective measurement of disease activity in patients with rheumatoid arthritis. Clin Exp Rheumatol 32(Suppl 85):S29\u2013S34","journal-title":"Clin Exp Rheumatol"},{"key":"3306_CR18","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1185\/03007995.2012.753042","volume":"29","author":"W Li","year":"2013","unstructured":"Li W, Sasso EH, Emerling D et al (2013) Impact of a multi-biomarker disease activity test on rheumatoid arthritis treatment decisions and therapy use. Curr Med Res Opin 29:85\u201392","journal-title":"Curr Med Res Opin"},{"key":"3306_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0047373","author":"B Wu","year":"2012","unstructured":"Wu B, Wilson A, Wang F et al (2012) Cost effectiveness of different treatment strategies in the treatment of patients with moderate to severe rheumatoid arthritis in China. PLoS One. doi: 10.1371\/journal.pone.0047373","journal-title":"PLoS One"},{"key":"3306_CR20","first-page":"85","volume":"7","author":"V Fragoulakis","year":"2015","unstructured":"Fragoulakis V, Vitsou E, Hernandez AC et al (2015) Economic evaluation of anti-TNF agents for patients with rheumatoid arthritis in Greece. Clinicoecon Outcomes Res 7:85\u201393","journal-title":"Clinicoecon Outcomes Res"},{"key":"3306_CR21","unstructured":"Thai Rheumatism Association (2008) Guideline for biological therapy in rheumatoid arthritis. http:\/\/www.thairheumatology.org\/download\/guideline_biolo_gic_therapy.pdf (Thai language) Accessed 1 December 2015"},{"key":"3306_CR22","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315\u2013324","journal-title":"Arthritis Rheum"},{"key":"3306_CR23","doi-asserted-by":"crossref","first-page":"R129","DOI":"10.1186\/ar2796","volume":"11","author":"M Osiri","year":"2009","unstructured":"Osiri M, Wongchinsri J, Ukritchon S et al (2009) Comprehensibility, reliability, validity and responsiveness of the Thai version of the Health Assessment Questionnaire in Thai patients with rheumatoid arthritis. Arthritis Res Ther 11:R129","journal-title":"Arthritis Res Ther"},{"key":"3306_CR24","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ymeth.2012.12.015","volume":"61","author":"EM Bartels","year":"2013","unstructured":"Bartels EM, Ribel-Madsen S (2013) Cytokine measurements and possible interference from heterophilic antibodies\u2014problems and solutions experienced with rheumatoid factor. Methods 61:18\u201322","journal-title":"Methods"},{"key":"3306_CR25","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(97)01300-7","volume":"350","author":"M Boers","year":"1997","unstructured":"Boers M, Verhoeven AC, Markusse HM et al (1997) Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 350:309\u2013318","journal-title":"Lancet"},{"key":"3306_CR26","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJMoa1303006","volume":"369","author":"JR O\u2019Dell","year":"2013","unstructured":"O\u2019Dell JR, Mikuls TR, Taylor TH et al (2013) Therapies for active rheumatoid arthritis after methotrexate failure. New Engl J Med 369:307\u2013318","journal-title":"New Engl J Med"},{"key":"3306_CR27","doi-asserted-by":"crossref","first-page":"h1046","DOI":"10.1136\/bmj.h1046","volume":"350","author":"DL Scott","year":"2015","unstructured":"Scott DL, Ibrahim F, Farewell V et al (2015) Therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis: TACIT non-inferiority randomised controlled trial. BMJ 350:h1046","journal-title":"BMJ"},{"key":"3306_CR28","first-page":"584","volume":"25","author":"P Alex","year":"2007","unstructured":"Alex P, Szodoray P, Knowlton N et al (2007) Multiplex serum cytokine monitoring as a prognostic tool in rheumatoid arthritis. Clin Exp Rheumatol 25:584\u2013592","journal-title":"Clin Exp Rheumatol"},{"key":"3306_CR29","doi-asserted-by":"crossref","first-page":"R784","DOI":"10.1186\/ar1733","volume":"7","author":"K Raza","year":"2005","unstructured":"Raza K, Falciani F, Curnow SJ et al (2005) Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stronal cell origin. Arthritis Res Ther 7:R784\u2013R795","journal-title":"Arthritis Res Ther"},{"key":"3306_CR30","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1136\/ard.2006.054924","volume":"66","author":"W Hueber","year":"2007","unstructured":"Hueber W, Tomooka BH, Zhao X et al (2007) Proteomic analysis of secreted proteins in early rheumatoid arthritis: anti-citrulline autoreactivity is associated with up regulation of proinflammatory cytokines. Ann Rheum Dis 66:712\u2013719","journal-title":"Ann Rheum Dis"},{"key":"3306_CR31","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1093\/rheumatology\/ker338","volume":"51","author":"HL Wright","year":"2012","unstructured":"Wright HL, Bucknall RC, Moots RJ et al (2012) Analysis of SF and plasma cytokines provides insights into the mechanisms of inflammatory arthritis and may predict response to therapy. Rheumatology (Oxford) 51:451\u2013459","journal-title":"Rheumatology (Oxford)"},{"key":"3306_CR32","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/nrrheum.2015.171","volume":"12","author":"IB McInnes","year":"2016","unstructured":"McInnes IB, Buckley CD, Isaacs JD (2016) Cytokines in rheumatoid arthritis-shaping the immunological landscape. Nat Rev Rheumatol 12:163\u2013168","journal-title":"Nat Rev Rheumatol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-016-3306-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-016-3306-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-016-3306-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,7]],"date-time":"2019-09-07T19:03:53Z","timestamp":1567883033000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-016-3306-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,17]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["3306"],"URL":"https:\/\/doi.org\/10.1007\/s10067-016-3306-x","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,17]]}}}